MedPath

Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)

Conditions
Dravet Syndrome
Registration Number
NCT04437004
Lead Sponsor
University of California, Los Angeles
Brief Summary

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Detailed Description

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Recruitment & Eligibility

Status
AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures.
Exclusion Criteria

Not provided

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of California, Los Angeles

🇺🇸

Los Angeles, California, United States

University of California, Los Angeles
🇺🇸Los Angeles, California, United States
Shaun Hussain, MD
Contact
310-206-4037
Angela L. Martinez
Contact
310-206-4037
angelamartinez@mednet.ucla.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.